Stimulants Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Stimulants stocks.

Stimulants Stocks Recent News

Date Stock Title
May 3 HRMY Harmony Biosciences Holdings First Quarter 2024 Earnings: EPS Beats Expectations
May 2 HRMY Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences is a Solid Choice
May 2 ZVRA Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
May 1 HRMY Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice
May 1 HRMY HRMY or TECH: Which Is the Better Value Stock Right Now?
May 1 HRMY Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call Transcript
May 1 ZVRA Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
Apr 30 HRMY Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
Apr 30 HRMY Harmony Biosciences: Company's Q1 Update Music To Investor Ears (Upgrade)
Apr 30 HRMY Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Call Transcript
Apr 30 HRMY Harmony Biosciences Holdings, Inc. 2024 Q1 - Results - Earnings Call Presentation
Apr 30 HRMY Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
Apr 30 HRMY Harmony Biosciences Exceeds Analyst Revenue Forecasts While Aligning with EPS Projections in Q1 2024
Apr 30 HRMY Harmony Biosciences acquires Epygenix gaining rare epilepsy pipeline
Apr 30 HRMY Harmony Biosciences Non-GAAP EPS of $0.88 beats by $0.10, revenue of $154.6M misses by $0.19M
Apr 30 HRMY Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
Apr 30 HRMY Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
Apr 29 HRMY Harmony Biosciences Q1 2024 Earnings Preview
Apr 29 ZVRA Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
Stimulants

Stimulants (also often referred to as psychostimulants or colloquially as uppers) is an overarching term that covers many drugs including those that increase activity of the central nervous system and the body, drugs that are pleasurable and invigorating, or drugs that have sympathomimetic effects. Stimulants are widely used throughout the world as prescription medicines as well as without a prescription (either legally or illicitly) as performance-enhancing or recreational drugs. The most frequently prescribed stimulants as of 2013 were lisdexamfetamine, methylphenidate, and amphetamine. It is estimated that the percentage of the population that has abused amphetamine-type stimulants (e.g., amphetamine, methamphetamine, MDMA, etc.) and cocaine combined is between 0.8% and 2.1%.

Browse All Tags